The Conversation (0)
Myriad Genetics (NASDAQ:MYGN), a global leader in personalized medicine, announced today that it has signed a new laboratory services agreement with Pfizer Inc. As quoted in the press release: Under the terms of the agreement, Myriad will provide BRACAnalysis CDx® testing in a Phase 2 study evaluating talazoparib, Pfizer’s investigational polymerase (PARP) inhibitor, for neo-adjuvant treatment …
Myriad Genetics (NASDAQ:MYGN), a global leader in personalized medicine, announced today that it has signed a new laboratory services agreement with Pfizer Inc.
As quoted in the press release:
Under the terms of the agreement, Myriad will provide BRACAnalysis CDx® testing in a Phase 2 study evaluating talazoparib, Pfizer’s investigational polymerase (PARP) inhibitor, for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer.
“We are excited to be providing BRACAnalysis CDx testing in this neo-adjuvant breast cancer trial,” said Lloyd Sanders, president of Oncology at Myriad Genetics, Inc. “We believe this agreement underscores Myriad’s leadership in the field of companion diagnostics for PARP inhibitors, and we look forward to making genetic testing more accessible for patients.”
Every year in the United States approximately 35,000 women are diagnosed with new cases of triple negative breast cancer, which has significantly lower survival rates and limited treatment options when compared to other types of breast cancer.